Catalyst Pharmaceuticals, Inc.
CPRX
Rang in Aktien
#4162
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Aktienkurs
$31.49
Zuletzt synchronisiert: 2026-07-21
Marktkapitalisierung
$3.85B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
49.88%
Land
US
Handel Catalyst Pharmaceuticals, Inc. (CPRX)
Kategorie
Healthcare
Gewinn für Catalyst Pharmaceuticals, Inc. (CPRX)
Gewinn im Mar 2026 TTM: $296.46M
Laut den aktuellen Finanzberichten von Catalyst Pharmaceuticals, Inc. betragen die aktuellen Gewinne des Unternehmens $296.46M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $94.51M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2022, der $104.72M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Catalyst Pharmaceuticals, Inc. von 2002 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $296.46M | 37.08% |
| 2024 | $216.26M | 128.82% |
| 2023 | $94.51M | -9.75% |
| 2022 | $104.72M | 98.83% |
| 2021 | $52.67M | 25.73% |
| 2020 | $41.89M | 25.39% |
| 2019 | $33.41M | -198.25% |
| 2018 | $-34.00M | 84.68% |
| 2017 | $-18.41M | 1.88% |
| 2016 | $-18.07M | -10.68% |
| 2015 | $-20.23M | 30.46% |
| 2014 | $-15.51M | 27.60% |
| 2013 | $-12.15M | 198.17% |
| 2012 | $-4.08M | -36.22% |
| 2011 | $-6.39M | 59.52% |
| 2010 | $-4.01M | -44.68% |
| 2009 | $-7.24M | -31.45% |
| 2008 | $-10.56M | 155.21% |
| 2007 | $-4.14M | 51.66% |
| 2006 | $-2.73M | 51.18% |
| 2005 | $-1.81M | 234.44% |
| 2004 | $-539.82K | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $-255.95K | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | 1,679.31% |
US
|
|
| $-3.09B | -1,141.29% |
US
|
|
| $-4.02B | -1,454.73% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 557.99% |
NL
|
